

## Carbohydrate Deficient Transferrin And Forensic Medicine

Dr. Shilpa Singh<sup>1</sup>, Dr. Bhumija Siwach<sup>2</sup>, Dr. Vishwajeet Singh<sup>3</sup>

1. Assistant Professor, Department of Forensic Medicine, Santosh Deemed to be University, Ghaziabad
2. Tutor, Department of Forensic Medicine, Santosh Deemed to be University, Ghaziabad
3. Associate Professor, Department of Forensic Medicine, Santosh Deemed to be University, Ghaziabad

### ABSTRACT

The diagnosis of chronic alcohol consumption is challenging in forensic medicine. One of the most prevalent diagnostic indicators for identifying chronic alcohol abuse is carbohydrate deficient transferrin (CDT). Its diagnostic value is not entirely sensitive and specific, nevertheless. Pre-analytical difficulties, mutant transferrins, several metabolic illnesses, body composition, arterial hypertension, medication use, and exposure to chemical solvents are a few known cautions. It is necessary to read CDT analysis carefully in light of the many caveats. A balanced interpretation is required for forensic and occupational medicine applications, such as delegation to workplaces where alcoholism may have lethal repercussions or to get a driver's licence. A balanced interpretation is required for forensic and occupational medicine applications, such as delegation to workplaces where alcoholism may have lethal repercussions or to get a driver's licence. For these applications, capillary zone electrophoresis or high performance liquid chromatography are to be preferred for CDT analysis as their principal benefit is the separation of several CDT isoforms. The use of additional alternative tests, such as ethyl glucuronide and fatty acid ethyl esters in hair, can be taken into consideration in problematic circumstances.

### INTRODUCTION

Chronic alcohol consumption is challenging to identify because high amounts of many people downplay or deny their usage of alcohol, especially since diagnostic. There aren't many parameters with high sensitivity and specificity. From there is a requirement for early detection from both a medical and social perspective. Identification and accurate assessment of excessive alcohol use. Forensic medicine indicators include things like drunkenness. driving [1-3], reapplying for a licence [4], especially for professionals drivers, or a postmortem alcoholism diagnosis based on vitreous humour [5,6] compelling evidence is delegation in occupational medicine to places of employment where the effects of persistent alcohol use may have catastrophic repercussions, such as operating at high altitudes in aviation high elevations, working with hazardous chemicals, and operating potentially machines that pose a risk [7].

The criterion with the highest diagnostic efficacy among the currently employed laboratory tests is carbohydrate deficient transferrin (CDT) [8,9]. At least eight European nations regularly evaluate potential sober drivers using biomarkers to determine whether they are abstaining from alcohol. Repeat offenders are sent to rehabilitation in Switzerland, Italy, and

Austria, and biological indicators, such as CDT, are measured four times a year to track alcohol abstinence. The driver's licence is reinstated after a year if the treatment was effective and the biomarkers were maintained under control.

In general, CDT has a half-life of 14–17 days [10,11]. Compared to suggestive liver enzymes and mean corpuscular volume, CDT values fall more quickly, making them a useful measure in the early stages of alcohol withdrawal [12]. The premise of abstinence is supported by a declining CDT value if liver enzyme levels are still excessive.

### Alcoholic drivers

In "high-risk offenders," Morgan [4] looked into the potential influence of CDT values on the choice of whether to reapply for a licence. In 70% of the cases, CDT readings were helpful. In 8% of the cases, the CDT values would have caused the reapplication decision to alter, and in 22% of the cases, they may have caused confusion. Iffland [2] looked into the importance of CDT values in 534 drivers who were thought to have been driving while intoxicated. 20–25% of these drivers had significant alcohol-related issues. Over 20 U/L CDT values were present in 55% of the participants overall, and over 30 U/L CDT values were present in about 30% of the subjects (for units: see below). For the purpose of identifying drivers who abuse alcohol chronically, CDT was suggested as a useful criterion in conjunction with other widely used parameters.

### Pre-analytical aspects

Due to neuraminidase's cleavage of the transferrin molecule, bacterial or viral contamination may result in false-positive CDT results [13]. Long-term storage or shipping of uncentrifuged whole-blood samples may result in a rise in CDT levels [14]. Low diurnal fluctuation exists for CDT[15]. Therefore, it is not required to limit sample collection to a particular time of day. Samples of uncontaminated serum that were kept at 20 °C were stable for up to 8 years [14]. Repeated thawing and freezing had no discernible impact on CDT for frozen samples (20 °C) [16].

The N-Latex technique (Siemens), the ClinRep CDT HPLC method (Recipe), and the CEofix CDT CZE method (Analisis) were all determined by the Dutch CDT working group (NVKC) [30] to be suitable as standard forensic methods alongside the reference method [17]. The HPLC candidate reference method [13] is the standard (confirmatory) method for any medico-legal application of the CDT test with focus on the relative amount of dialotransferrin in Sweden for regranting a driver's licence after intoxicated driving.

All CDT immunoassay results for persons whose driving privileges have been previously revoked due to "drunk driving" must be verified by additional methods. CZE appears well adapted to becoming the method of choice due to its intrinsic qualities of high selectivity, simple operation, high productivity, and cheap operational costs [11].

### Analytical problems

By adding inulin to the fresh serum, one can activate the alternative complement pathway and transform native C3 into various degradation products whose electrophoretic mobility no longer coincides with the transferrin glycoforms, thereby reducing interference from complement C3 and its  $\gamma$ -globulin split products in the CZE analysis of CDT. Rapid CZE examination of CDT glycoforms is possible thanks to the inulin treatment [13]. In order to monitor unique and complex transferrin patterns, including those with genetic variations and abnormalities of glycosylation, CZE offers high-resolution separations of serum transferrin isoforms. Interference-free transferrin patterns are found, with the exception of specific samples from individuals with severe liver disorders and sera with high quantities of paraproteins [19]. Interferences in the beta region can be seen in advanced liver cirrhosis. There have been initiatives to find, lessen, or even get rid of these interferences.

In nonelectrophoretic or chromatographic analytical procedures, the transferrin subtype D may give false-positive results [15], whereas the transferrin subtype B may give false-negative results [16]. Varied ethnic origins have different allele frequencies for the different transferrin subtypes [17,18]. The prevalence of transferrin mutations is higher outside of Europe. Transferrin mutations are common, especially in native populations of America and Australia and in Africans. As a result, there is a higher chance of false positive and false negative outcomes among non-Caucasian populations. When utilising an adaptation of the reference values, it is still possible to measure alcohol consumption in transferrin CD heterozygotes using a chromatographic or electrophoretic approach [17].

### Adjustments of reference intervals

Over time, variations in basal and alcohol-related CDT levels have been noted in connection to variables such as age, gender, and body mass index (BMI). A study that measured individual transferrin glycoforms using an HPLC candidate reference method rather than a CDT fraction found that the earlier results were largely dependent on the measurement method and did not accurately reflect baseline differences or alcohol-induced changes in the transferrin glycoprotein complex. As a result, it is not necessary to change reference intervals for DST, the primary CDT glycoform, based on factors such as smoking, BMI, age, gender, or ethnic origin [14].

### Dose–response relation of CDT

A rather wide range of variation can be shown in the dose-response relationship between daily ethanol intake in the range of 0-70 g and the CDT value [15]. The connection between alcohol consumption and CDT dose-response is greatly influenced by total body water [16]. Smoking, metabolic syndrome elements, and BMI all significantly increased the likelihood of an abnormal CDT result when heavy alcohol use was present. CDT is a subpar indicator of excessive alcohol use in both overweight or obese women and men. CDT is less effective in nonsmokers as well. Smoking and obesity don't seem to have method-specific impacts [13,17].

The CDT response to heavy alcohol consumption is suppressed by high blood pressure (or a trait related to it). Metabolic syndrome and alcoholism are frequently linked to hypertension (especially diastolic hypertension) alone [15]. A connection to insulin resistance, often known as

"syndrome X," has been suggested by the connections between CDT response and alcohol and smoking, plasma lipids and lipoproteins, obesity, and hypertension [13]. Low CDT concentrations were more common in hypertensive individuals with insulin resistance, as determined by hyperinsulinemic euglycemic clamp trials [16].

Patients with simultaneous kidney and pancreas transplants (who develop hyperinsulinemia as a result of the pancreatic venous drainage connecting to the systemic circulation) frequently had elevated CDT concentrations [17]. These data suggest that the establishment of circulating CDT concentrations involves insulin or insulin resistance. Although high blood pressure affects CDT and its reaction to alcohol in some ways, it has less of an impact than BMI or obesity-related factors like triglycerides or HDL cholesterol. Per se, there was no discernible relationship between blood pressure and CDT [7].

### **Drug interactions**

The impact of using contraceptives on CDT levels is debatable according to earlier immunoassay literature [11,12]. However, postmenopausal women's CDT values were lower [13]. Compared to postmenopausal women without oestrogen replacement, those on oestrogen replacement therapy exhibited higher CDT readings. Age-related impacts were not seen in men. Pregnant women's CDT readings were shown to be higher. Lower CDT levels were seen in postmenopausal women and in women using oral contraceptives [13]. Alcohol use, female sex, and bupropion use were all linked to elevated CDT levels [15]. Lower CDT levels were linked to two more medication classes: tricyclic antidepressants and angiotensin II receptor blockers. However, alcohol consumption confuses the effects of bupropion and tricyclic antidepressants on CDT levels. Angiotensin II receptor blockers, one of just 20 medication types, had an impact on CDT levels in the primary care sample. Disulfiram, an alcohol-deterrent medication, has no impact on CDT results. Therefore, lowering CDT levels during disulfiram treatment are appropriate for relapse prevention [16].

### **CONCLUSION**

One method for clarifying potential alcohol abuse is the detection of CDT levels [8,8,11]. It is important to recognise the psychological pressure that people will experience upon learning that a long-term alcohol consumption biomarker would be used. The disclosure of CDT decision may account for the high validity of self-reported alcohol consumption in alcoholics [12].

If patients are focusing on low-dose exposures to other chemicals as the root of their issues, this might be of interest to them. Patients may lie about their real alcohol consumption in certain circumstances in order to avoid losing reimbursement. Patients may even mistakenly imply exposure to low amounts of potentially hazardous substances like chlorinated hydrocarbons or by significantly less toxic nonchlorinated solvents, other low-level indoor pollution, or consumption of food that may have been very slightly contaminated with hepatotoxins.[30] These factors make it difficult to apply CDT in a forensic setting. Confounding variables must be considered while interpreting CDT results. It should be emphasised that

traditional CDT determination techniques were less reliable and more prone to limitations than contemporary CDT assays. Attention must be given to the method-dependent cut-off limits for CDT for forensic purposes. The use of CZE and HPLC procedures is advised since they enable the visualisation of all transferrin isoforms [3,29]. Since analytical interferences are partially assay dependent, adopting a confirmatory CDT method can further reduce analytical mistakes. Alternative tests may be quite helpful in questionable circumstances.

## REFERENCES

- [1] Iffland R, Grassnack F. Epidemiologic study of CDT (carbohydrate-deficient transferrin) and other indicators of alcohol problems in high blood alcohol German automobile drivers. *Blutalkohol* 1995;32:26–41 (in German).
- [2] Bortolotti F, Trettene M, Gottardo R, Bernini M, Ricossa MC, Tagliaro F. Carbohydrate-deficient transferrin (CDT): a reliable indicator of the risk of driving under the influence of alcohol when determined by capillary electrophoresis. *Forensic Sci Int* 2007;170:175–8.
- [3] Osuna E, Perez-Carceles MD, Moreno M, et al. Vitreous humor carbohydrate-deficient transferrin concentrations in the postmortem diagnosis of alcoholism. *Forensic Sci Int* 2000;108:205–13.
- [4] Berkowicz A, Wallerstedt S, Wall K, Denison H. Carbohydrate-deficient transferrin in vitreous humour: a marker of possible withdrawal-related death in alcoholics. *Alcohol Alcohol* 2001;36:231–4.
- [5] Golka K, Wiese A. Carbohydrate-deficient transferrin (CDT) — a biomarker for longterm alcohol consumption. *J Toxicol Environ Health B Crit Rev* 2004;7:319–37. [13] L. Thomas (2000) *Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik* 5. erw. Auflage. Frankfurt/Main: TH-Books-Verl.-Ges. - Hrsg.
- [6] Arndt T, Kropf J. A prolonged time interval between blood sample collection and centrifugation causes an increase in serum carbohydrate-deficient transferrin. *Med Sci Monit* 2002;8:BR61–4.
- [7] Mårtensson O, Schink E, Brandt R. Diurnal variability and in vitro stability of carbohydrate-deficient transferrin. *Clin Chem* 1998;44:2226–7.
- [8] Appenzeller BMR, Wennig R. Altered distribution of transferrin isoforms according to serum storage conditions. *Clin Chem* 2005;51:2159–62.
- [9] Helander A, Husa A, Jeppsson JO. Improved HPLC method for carbohydrate-deficient transferrin in serum. *Clin Chem* 2003;49:1881–90.
- [10] Jeppsson JO, Arndt T, Schellenberg F, et al. Towards standardization of CDT measurement. *Clin Chem Lab Med* 2007;45:558–62.

- [11] Oberrauch W, Bergman AC, Helander A. HPLC and mass spectrometric characterization of a candidate reference material for the alcohol biomarker carbohydrate-deficient transferrin (CDT). *Clin Chim Acta* 2008;395:142–5.
- [12] Bianchi V, Arfini C, Helander A. Determination of carbohydrate-deficient transferrin (CDT) in Italy. *Clin Chem Lab Med* 2008;46:1759–62.
- [13] Helander A, Bergström JP. Determination of carbohydrate-deficient transferrin in human serum using the Bio-Rad %CDT by HPLC test. *Clin Chim Acta* 2006;371:187–90.
- [14] Joneli J, Lanz C, Thormann W. Capillary zone electrophoresis determination of carbohydrate-deficient transferrin using the new CEofix reagents under high resolution condition. *J Chromatogr A* 2006;1130:272–80. Bortolotti F, Tagliaro F, Cittadini F, Gottardo R, Trettene M, Marigo M. Determination of CDT, a marker of chronic alcohol abuse, for driving license issuing: immunoassay versus capillary electrophoresis. *Forensic Sci Int* 2002;128:53–8.
- [15] Lanz C, Falmagne JB, de l'Escaille F, Marti U, Thormann W. Determination of carbohydrate-deficient transferrin in human serum with capillary zone electrophoresis. Sample preparation strategies for the removal of interferences caused by increased levels of immunoglobulins. *J Chromatogr A* 2008;1206:33–40.
- [16] Beisler AT, Kelly RH, Landers JP. Circumventing complement C3 interference in the analysis of carbohydrate-deficient transferrin in fresh serum. *Anal Biochem* 2000;285:143–50.
- [17] Schellenberg F, Menetrey L, Girre C, Nalpas B, Pagès JC. Automated measurement of carbohydrate-deficient transferrin using the Bio-Rad %CDT by the HPLC test on a Variant™ HPLC system: evaluation and comparison with other routine procedures. *Alcohol Alcohol* 2008;43:569–76.
- [18] Bean P, Peter JB. Allelic D variants of transferrin in evaluation of alcohol abuse: differential diagnosis by isoelectric focusing-immunoblotting-laser densitometry. *Clin Chem* 1994;40:2078–83.
- [19] Arndt T, Guessregen B, Hallermann D, Nauck M, Terjung D, Weckesser H. Forensic analysis of carbohydrate-deficient transferrin (CDT) by HPLC-statistics and extreme CDT values. *Forensic Sci Int* 2008;175:27–30.
- [20] Wuyts B, Delanghe JR, Kasvosve I, Gordeuk VR, Gangaidzo IT, Gomo ZA. Carbohydrate-deficient transferrin and chronic alcohol ingestion in subjects with transferrin CD-variants. *Clin Chem Lab Med* 2001;39:937–43.
- [21] Cavalli-Sforza L, Menozzi P, Piazza A. The history and the geography of human genes. Princeton, NJ: Princeton University Press; 1994. p. 158–94.
- [22] Helander A, Bergström J, Freeze HH. Testing for congenital disorders of glycosylation by HPLC measurement of serum transferrin glycoforms. *Clin Chem* 2004;50:954–8. Frezza M,

diPadova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. *N Engl J Med* 1990;322:95–9.

[23] Kodavali L, Townsend RR. Alcohol and its relationship to blood pressure. *Curr Hypertens Rep* 2006;8:338–44.

[24] Fagerberg B, Agewall S, Berglund A, Wysocki M, Lundberg PA, Lindstedt G. Is carbohydrate-deficient transferrin in serum useful for detecting excessive alcohol consumption in hypertensive patients? *Clin Chem* 1994;40:2057–63.

[25] Arndt T, Hackler R, Muller T, Kleine TO, Gressner AM. Increased serum concentration of carbohydrate-deficient transferrin in patients with combined pancreas and kidney transplantation. *Clin Chem* 1997;43:344–51.

[26] Arndt T, Erkens M, Holtkamp K, Keller T, Gressner AM. High prevalence of increased trisialotransferrin concentrations in patients with anorexia nervosa: Implications for determination of carbohydrate-deficient transferrin. *Clin Chim Acta* 2007;379:150–3.

[27] De Feo TM, Fargion S, Duca L, et al. Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. *Hepatology* 1999;29:658–63.

[28] Mundt MP, Kraus CK, Fleming MF. Potential drug interactions with the percent carbohydrate-deficient transferrin (%CDT) test, a new alcohol biomarker. *Pharmacotherapy* 2004;24:831–7.

[29] Helander A, Carlsson S. Carbohydrate-deficient transferrin and gamma-glutamyl transferase levels during disulfiram therapy. *Alcohol Clin Exp Res* 1996;20:1202–5.

[30] Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. Phosphatidylethanol (Peth) concentrations in blood are correlated to reported alcohol intake in alcoholdependent patients. *Alcohol* 2006;41:431–7.